A Phase 1/2 interventional study of KYV-101 anti-CD19 CAR-T cell therapy and Standard lymphodepletion regimen in Lupus Nephritis, Lupus Nephritis - WHO Class III and Lupus Nephritis - WHO Class IV, sponsored by Kyverna Therapeutics. Terminated at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Kyverna Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Lupus Nephritis with a site in Germany — 4 open to participants now, 9 under way, 3 of them phase 3. Lupus Nephritis · Germany.
Among the 32 studies in Lupus Nephritis with a site in Germany, this one is the 28th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 1/2, and was the 26th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →4 of the 32 studies in Lupus Nephritis with a site in Germany are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Germany, United States, France and 3 more countries
Ages 18–60
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
CRISPR Therapeutics · Sites in Germany, United States, Spain
Ages 18–70
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 9
First in 2003; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 100 across the 29 interventional studies, 79 across the 3 observational. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 32 have an industry lead sponsor. The 10 most frequent:
Kyverna Therapeutics is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Kyverna Therapeutics has 3 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Lupus Nephritis with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Lupus Nephritis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of organ involvement and disease severity. Renal involvement (categorized as lupus nephritis [LN]) may occur in approximately 50% of SLE patients and is marked by proteinuria, microscopic hematuria, and varying degrees of renal insufficiency. B cells play a central role in the pathogenesis of SLE and LN, with autoantibodies developing as an early finding, and local, tissue resident B cells producing pathogenic autoantibodies and driving inflammation and tissue damage over time. CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory lupus nephritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous or concurrent with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing with KYV-101 CAR T cells
Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen
Recommended Phase 2 Dose
Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen
KYV-101 anti-CD19 CAR-T cell therapy
Standard lymphodepletion regimen
Also known as: Cyclophosphamide, Fludarabine
Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)
Time frame: Up to 2 years
Frequency of dose limiting toxicities (Phase 1)
Time frame: Up to 2 years
To characterize the pharmacokinetics (PK) (Phase 1 and 2)
Levels of KYV-101 CAR-positive T cells in the blood
Time frame: Up to 2 years
To characterize the pharmacokinetics (PK) (Phase 1 and 2)
Levels of KYV-101 CAR Transgene
Time frame: Up to 2 years
To characterize the pharmacodynamics (PD) (Phase 1 and 2)
Levels of B cells in the blood
Time frame: Up to 2 years
To characterize the pharmacodynamics (PD) (Phase 1 and 2)
Levels of systemic cytokine concentrations in serum
Time frame: Up to 2 months
To evaluate disease related biomarkers (Phase 1 and 2)
Levels of anti-double stranded DNA (anti-dsDNA) in serum
Time frame: Up to 2 years
To evaluate disease related biomarkers (Phase 1 and 2)
Levels of complement C3, C4 in serum
Time frame: Up to 2 years
To evaluate efficacy of KYV-101 (Phase 1 and 2)
Complete renal response rates (CRR)
Time frame: 12, 24, and 52 weeks
To evaluate efficacy of KYV-101 (Phase 1 and 2)
Time to Complete renal response (CRR)
Time frame: Up to 2 years
To evaluate efficacy of KYV-101 (Phase 1 and 2)
Time from first achieved Complete renal response (CRR) to disease worsening or end of study
Time frame: Up to 2 years
To evaluate the immunogenicity (humoral response) of KYV-101 (Phase 1 and 2)
Percentage of participants who develop anti-KYV-101 antibodies by immunoassays
Time frame: Up to 2 years
To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)
Change from baseline in 36-Item Short Form Survey (SF-36)
Time frame: Up to 2 years
To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)
Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F)
Time frame: Up to 2 years
To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)
Change from baseline in Lupus Quality of Life (Qol) Questionnaire
Time frame: Up to 2 years
To access Patient Related Outcome (PRO) after infusion of KYV-101 (Phase 1 and 2)
Change from baseline in Work Productivity and Activity Impairment (WPAI)
Time frame: Up to 2 years
To define the recommended Phase 2 dose (Phase 1)
Time frame: Up to 2 years
Plan to share: No
Ran from Dec 2022 to primary completion in Dec 2025, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mivocabtagene autoleucel
Kyverna Therapeutics